MARKET

CDAK

CDAK

Codiak Biosciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.880
-0.760
-20.88%
Closed 19:56 06/30 EDT
OPEN
3.550
PREV CLOSE
3.640
HIGH
3.550
LOW
2.830
VOLUME
410.24K
TURNOVER
--
52 WEEK HIGH
22.95
52 WEEK LOW
2.210
MARKET CAP
64.78M
P/E (TTM)
-1.8328
1D
5D
1M
3M
1Y
5Y
CELU, CDAK and VLCN among mid-day movers
Gainers: Northern Lights Acquisition NLIT +149%. NeuroSense Therapeutics NRSN +42%. Rapid Micro Biosystems RPID +36%. ...
Seekingalpha · 17h ago
Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity
Codiak BioSciences Inc (NASDAQ: CDAK) announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials. In an open-label Phase 1 trial, exoIL-12 demonstrated a differentia...
Benzinga · 21h ago
Codiak Sees 'Platform-Validating' Data From Early Trials of Engineered Exosome Candidates
MT Newswires · 22h ago
BRIEF-Codiak Provides Platform-Validating Clinical Update And Data From Phase 1 Trials Of Exosting And Exoil-12
BRIEF-Codiak Provides Platform-Validating Clinical Update And Data From Phase 1 Trials Of Exosting And Exoil-12
Reuters · 1d ago
Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™
– Codiak’s engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest allowing for increased therapeutic window – – exoSTING and exoIL-12 demonstrated favorable safety and toler...
GlobeNewswire · 1d ago
Codiak begins dosing in early-stage trial for liver, gastric, colorectal cancers
Codiak BioSciences (NASDAQ:CDAK) <a href="https://seekin...
Seekingalpha · 1d ago
BRIEF-Codiak Initiates Patient Dosing In Phase 1 Clinical Trial Of Exoaso-Stat6 In Patients With Advanced Hepatocellular Carcinoma, Liver Metastases From Primary Gastric Cancer And Colorectal Cancer
BRIEF-Codiak Initiates Patient Dosing In Phase 1 Clinical Trial Of Exoaso-Stat6 In Patients With Advanced Hepatocellular Carcinoma, Liver Metastases From Primary Gastric Cancer And Colorectal Cancer
Reuters · 1d ago
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak’s engEx® Platform to enter clinical development CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical com...
GlobeNewswire · 1d ago
More
No Data
Learn about the latest financial forecast of CDAK. Analyze the recent business situations of Codiak Biosciences, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CDAK stock price target is 11.33 with a high estimate of 17.00 and a low estimate of 8.00.
High17.00
Average11.33
Low8.00
Current 2.880
EPS
Actual
Estimate
-0.66-0.260.140.53
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 63
Institutional Holdings: 14.22M
% Owned: 63.21%
Shares Outstanding: 22.49M
TypeInstitutionsShares
Increased
10
290.85K
New
16
374.63K
Decreased
16
276.40K
Sold Out
5
6.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.17%
Pharmaceuticals & Medical Research
-0.21%
Key Executives
Non-Executive Chairman/Independent Director
Steven Gillis
President/Chief Executive Officer/Director
Douglas Williams
Chief Financial Officer/Treasurer
Linda Bain
Executive Vice President/Chief Compliance Officer/Secretary
Yalonda Howze
Senior Vice President/Director of Human Resources
Nicole Barna
Chief Technology Officer
Konstantin Konstantinov
Chief Scientific Officer
Sriram Sathyanarayanan
Other
Richard Brudnick
Other
David Mauro
Independent Director
Karen Bernstein
Independent Director
Charles Cooney
Independent Director
Anne-Virginie Eggimann
Independent Director
Jason Haddock
Independent Director
Theo Melas-Kyriazi
Independent Director
Lini Pandite
No Data
No Data
About CDAK
Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The Company's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The Company's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).

Webull offers kinds of Codiak BioSciences Inc stock information, including NASDAQ:CDAK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDAK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDAK stock methods without spending real money on the virtual paper trading platform.